Brent crude sustained at $70/barrel and above, could require future fuel price reviews    2021 International Women's Day highlights transformative power of equal participation: UN    Bibliotheca Alexandrina presents webinar on Arab-Islamic Heritage    Pope Francis calls for peace in Iraq's post-IS Mosul    Egypt's Al-Sisi orders increasing medical convoys, mobile clinics under ‘Decent Life' initiative    Egypt's Shoukry, UN representative discuss ways to achieve political settlement in Libya    Egypt's stocks start week in green, benchmark EGX 30 climbs 1.98%    National Bank of Egypt chairman named among Forbes Middle East's Top 100 CEOs list    Egypt's net foreign reserves rise to $40.2 billion at February-end: c.bank    JICA to continue supporting Egypt's educational reforms to boost women's empowerment, gender equality    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    Capital Intelligence confirms Egypt's sovereign ratings with stable outlook    Sisi approves amending law honoring martyrs, victims, missing, injured in terror attacks    Government inaugurates ICT projects in Kafr El-Sheikh    Saudi-led coalition destroys eight Houthi drones: Saudi TV    Train derails killing 1, injuring 40 in southern Pakistan    Egypt condemns latest terror atack in Somalia    Live score: Liverpool v Fulham (English Premier League)    Pope visits Iraq's war-ravaged north on last day of tour    Egypt detects 588 new coronavirus cases, 38 deaths on Saturday    Messi provides 2 assists for Barca ahead of Madrid derby    Nigeria's Iheanacho, Ghana's Amartey give Leicester win over Brighton    US envoy seeking support to shakeup Afghan peace process, warring parties object    Al-Sisi, Al-Burhan to intensify efforts towards reaching legally binding GERD agreement    UK calls on African countries to join UK-Egypt led Adaptation Action Coalition    Egypt's Shoukry, UN Secretary-General discuss Ethiopia's Nile dam developments    World Bank approves $440 million for enhancing Egypt's railways    Al-Sisi visits Sudan for first time after formation of new transitional government    Art House partners with Cultural Development Fund to present theatrical, musical shows    Egypt stresses necessity of launching 'serious' negotiation process to reach deal on GERD before flood season    Messi serves as bright spot in Barcelona's disastrous season    Zamalek ready with striking force against Esperance Tunis    Egypt clubs protest Football Association decision to cover costs of COVID-19 tests    Hassan Allam wins contract to manage, operate Grand Egyptian Museum    Sudan keen to enhance cooperation with Egypt: Sudanese FM Al-Mahdi    Egypt court upholds 3-year prison sentence for Mubarak-era Minister El-Feky    A Happy Purrfect Rescue Story of 4 Cats in Thailand    Egypt's Zamalek arrive in Tunisia to face Esperance in CAF Champions League    Winston Churchill's Moroccan landscape painting owned by Angelina Jolie sells for $11.5M    Orascom Construction to build Magdi Yacoub Global Heart Centre    Respect for diversity    Huawei launches HUAWEI FreeLace Pro in Egypt with extra-long battery life and top-grade noise cancellation    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    1st hours of registration for coronavirus vaccine seen 7,000 Egyptians signing up: ministry    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Egypt, Ethiopia, Sudan to resume Nile dam talks today    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





South African virus variant may resist antibody drugs; Pfizer/BioNTech vaccine seems to work vs UK variant
Published in Ahram Online on 25 - 01 - 2021

South African variant may resist current antibody treatments
The variant of the new coronavirus identified in South Africa can resist, or "escape," antibodies that neutralize earlier versions of the virus, scientists have found. It "exhibits complete escape" from three classes of monoclonal antibodies manufactured for treating COVID-19 patients, and it shows "substantial or complete" resistance to neutralizing antibodies in blood donated by COVID-19 survivors, the scientists reported on Tuesday on bioRxiv ahead of peer review. Similarities between the South Africa variant and another variant identified in Brazil suggest the Brazilian variant will show similar resistance, they added.
Liam Smeeth of the London School of Hygiene and Tropical Medicine, who was not involved in the study, noted that these were laboratory tests, and it would be unwise to extrapolate the findings to humans at this point. "The data do raise the possibility that the protection gained from past infection with COVID-19 may be lower for re-infection with the South African variant," he said. "The data also suggest that the existing vaccines could be less effective against the South African variant." He called for large studies among populations where the variant is common.
Pfizer/BioNTech shot likely protects against UK variant
The COVID-19 vaccine from Pfizer Inc and BioNTech SE is likely to protect against the more infectious variant of the virus discovered in Britain and now spreading around the world, according to laboratory tests. Researchers took blood samples from 16 people who had received the vaccine and exposed the blood to a synthetic virus, or pseudovirus, that was engineered to have 10 mutations found in the UK variant.
The antibodies that had developed in response to the vaccine effectively neutralized the pseudovirus, according to a report posted on Tuesday on bioRxiv ahead of peer review.
"This makes it very unlikely that the UK variant will escape from the protection provided by the vaccine," said Jonathan Stoye, a virus scientist at Britain's Francis Crick Institute who was not involved in the research. Similar experiments are needed with the more concerning variant first found in South Africa, he suggested. AstraZeneca Plc, Moderna Inc and CureVac NV are also testing whether their respective vaccines will protect against the fast-spreading variants.
Immune system will remember how to make COVID-19 antibodies
People who have recovered from COVID-19 can likely mount a fast and effective response to the virus if they encounter it again because their immune system's "B cells" will remember how to make the antibodies needed to fight it, a new study shows.
Researchers tracked 87 COVID-19 survivors for six months and found that while levels of antibodies to the virus may decline over time, the number of memory B cells remains unchanged. The antibodies produced by these cells are more potent than the patients' original antibodies and may be more resistant to mutations in the spike protein the virus uses to break into cells, they said. For example, they found, the antibodies could recognize and neutralize at least one of the mutations in the South African variant of the virus that has caused concern among health experts.
Even if antibody levels fall, B cells will remember how to make them when necessary, according to study leader Michel Nussenzweig of Rockefeller University, whose findings were reported on Monday in Nature. If this is true at six months, as in this study, it is safe to assume it is probably still true for longer periods, he added. People who have recovered from COVID-19 "may become infected but the immune system will be prepped to fight off the infection," Nussenzweig said.
Mortality higher when ICUs are packed with COVID-19 patients
The more full an intensive care unit (ICU) is with COVID-19 patients, the higher the mortality rate among those patients, new data suggest. When researchers tracked outcomes of 8,515 COVID-19 patients admitted to 88 U.S. Veterans Affairs hospitals in 2020, they found that survival rates improved between March and August.
Throughout the study period, however, the risk of death was nearly double when at least 75% of ICU beds were filled with COVID-19 patients, compared to when they accounted for no more than 25% of ICU beds.
COVID-19 mortality "increases during periods of peak demand," said Dr. Dawn Bravata of the Richard L Roudebush VA Medical Center in Indianapolis who co-led the study published on Tuesday in JAMA Network Open.
"The more the public can do to avoid infections, the better," she added. In addition, Bravata said, "facilities within a healthcare system or within a geographic region should collaborate to triage critically ill patients with COVID-19 to sites with greater ICU capacity to reduce strain on any one facility."


Clic here to read the story from its source.